Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 1, 2010, Pages 75-81

  Kuo, Yuan Hung ^a   Chen, Chien Hung ^a   Wang, Jing Houng ^a   Hung, Chou Hung ^a   Tseng, Po Lin ^a   Lu, Sheng Nan ^a   Changchien, Chi Sin ^a   Lee, Chuan Mo ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Consolidation therapy; Hepatitis B; Relapse; Sustained response; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SEROCONVERSION; TAIWAN; TREATMENT DURATION;

ADULT; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 73649106165     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903394550     Document Type: Article

References (34)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990;8:518-520
2. Lok AS, Heathcote EJ, Hoofnagel JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001;120:1828-1853
3. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988;8:493-496
4. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 1981;2:1129-1133
5. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993;262:369-370
6. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2̀, 3̀-dideoxy- 3̀-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499
7. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180
8. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1532
9. Liaw YF. Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol 1997;12:S346-53.
10. Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, et al. Extended lamivudine retreatment for chronic hepatitis: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-1087
11. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-755
12. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. The Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68
13. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis Be. antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806
14. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine induced HBeAg seroconversion. J Viral Hepat 2002;9:208-212
15. Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, et al. Durability of lamivudine induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002;37:669-674
16. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-1273
17. Byun KS, Kwon OS, Kim JH, Yim HJ, Chang YJ, Kim JY, et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol 2005;20:1838-1842
18. Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 2005;48:341-349
19. Ryu SH, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg seroconversion. J Hepatol 2003;39:614-619
20. Lok SF, McMahon BJ. AASLD practice guidelines: Chronic hepatitis B. Hepatology 2007;45:507-539
21. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005;25:472-489
22. Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003;38:153-157
23. Chen CH, Eng HL, Lee CM, Kuo FY, Lu SN, Huang CM, et al. Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma. Hepatogastroenterology 2004;51:552-555
24. LeeCM,ChenCH,LuSN,TungHD,ChouWJ,WangJH,etal. Prevalence of clinical implications of hepatitisBvirus genotypes in southern Taiwan. Scand J Gastroenterol 2003;1:95-101.
25. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
26. Davis GL, Hoofnagle JH. Reactivation of chronic hepatitis B infection. Gastroenterology 1987;92:2028-2031
27. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-971
28. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975
29. Fourel I, Cullen JM, Saputelli J, Aldrich CE, Schaffer P, Averett DR, et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994;68:8321-8330
30. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998;245:18-32.
31. Chen CH, Lee CM, Lu SN, Wang JH, Tung HD, Hung CH, et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004;41:454-461
32. Van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-424
33. Chen CH, Lee CM, Lu SN, Changchien CS, Wang JC, Wang JH, et alComparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 2006;:76-82.
34. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-1527